RS62244B1 - Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba - Google Patents

Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba

Info

Publication number
RS62244B1
RS62244B1 RS20211041A RSP20211041A RS62244B1 RS 62244 B1 RS62244 B1 RS 62244B1 RS 20211041 A RS20211041 A RS 20211041A RS P20211041 A RSP20211041 A RS P20211041A RS 62244 B1 RS62244 B1 RS 62244B1
Authority
RS
Serbia
Prior art keywords
cdkl5
nucleic acid
fusion protein
protein
tatk
Prior art date
Application number
RS20211041A
Other languages
English (en)
Serbian (sr)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of RS62244B1 publication Critical patent/RS62244B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
RS20211041A 2014-02-28 2015-02-27 Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba RS62244B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
EP19179287.8A EP3608334B1 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (1)

Publication Number Publication Date
RS62244B1 true RS62244B1 (sr) 2021-09-30

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20211041A RS62244B1 (sr) 2014-02-28 2015-02-27 Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba
RSP20191144 RS59344B1 (sr) 2014-02-28 2015-02-27 Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba

Family Applications After (1)

Application Number Title Priority Date Filing Date
RSP20191144 RS59344B1 (sr) 2014-02-28 2015-02-27 Tatk-cdkl5 fuzioni proteini, sastavi, formulacije i njihova upotreba

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2745335T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE055282T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3608334T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
CA3229127A1 (en) * 2021-08-18 2023-02-23 Julie Yu Wei Recombinant aav formulations
CN116874571A (zh) * 2021-12-17 2023-10-13 博格隆(上海)生物技术有限公司 突变的蛋白a结构域c及其应用
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609640A (en) * 2010-10-25 2015-06-26 Univ D’Aix Marseille Treatment of mecp2-associated disorders
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása

Also Published As

Publication number Publication date
IL247481A0 (en) 2016-11-30
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
IL275435A (en) 2020-08-31
EP3608334A1 (en) 2020-02-12
LT3110837T (lt) 2019-10-10
ZA201606655B (en) 2020-05-27
US20160194617A1 (en) 2016-07-07
HUE045393T2 (hu) 2019-12-30
EA038000B1 (ru) 2021-06-22
US9290746B2 (en) 2016-03-22
DK3608334T3 (da) 2021-08-23
PH12016501689B1 (en) 2016-10-03
AU2015221860A1 (en) 2016-09-08
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
MX2016011167A (es) 2017-04-06
CR20160392A (es) 2017-06-12
US20180327725A1 (en) 2018-11-15
CA2940401C (en) 2022-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX392778B (es) 2025-03-24
JP2017507655A (ja) 2017-03-23
AU2015221860B2 (en) 2019-09-12
IL247481B (en) 2020-07-30
PL3110837T3 (pl) 2020-04-30
US10584318B2 (en) 2020-03-10
CY1124727T1 (el) 2022-07-22
CL2016002142A1 (es) 2017-09-08
JP6629747B2 (ja) 2020-01-15
KR102307276B1 (ko) 2021-09-30
SMT202100478T1 (it) 2021-09-14
US10907138B2 (en) 2021-02-02
HUE055282T2 (hu) 2021-11-29
EP3608334B1 (en) 2021-05-19
ES2745335T3 (es) 2020-02-28
DOP2016000220A (es) 2016-12-15
WO2015128746A3 (en) 2015-11-26
KR20170002372A (ko) 2017-01-06
WO2015128746A2 (en) 2015-09-03
AU2019219743B2 (en) 2020-10-29
SI3608334T1 (sl) 2021-11-30
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
EP3110837B1 (en) 2019-06-12
SG11201606863YA (en) 2016-09-29
US20200199549A1 (en) 2020-06-25
JP6896050B2 (ja) 2021-06-30
PT3110837T (pt) 2019-09-12
SG10202000537RA (en) 2020-03-30
SI3110837T1 (sl) 2019-12-31
NI201600127A (es) 2017-03-13
EP3110837A2 (en) 2017-01-04
NZ723371A (en) 2023-11-24
EA201691691A1 (ru) 2017-05-31
SV2016005264A (es) 2017-02-15
SMT201900504T1 (it) 2019-11-13
PT3608334T (pt) 2021-08-25
BR112016019868A2 (pt) 2017-10-17
JP2020062022A (ja) 2020-04-23
PL3608334T3 (pl) 2021-11-22
HRP20191511T1 (hr) 2019-11-29
PH12016501689A1 (en) 2016-10-03
PE20161406A1 (es) 2017-01-14
ES2885245T3 (es) 2021-12-13
BR112016019868B1 (pt) 2023-11-28
HRP20211324T1 (hr) 2021-11-26
MX2020001223A (es) 2022-05-31
CA2940401A1 (en) 2015-09-03
RS59344B1 (sr) 2019-10-31
US9944910B2 (en) 2018-04-17
EA202190727A2 (ru) 2021-07-30
AU2019219743A1 (en) 2019-09-19
US20150247134A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
US10907138B2 (en) TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
JP2017507655A5 (enExample)
US20210268072A1 (en) TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
US9616138B1 (en) Cargo carrying nanoparticles
US11603394B2 (en) Targeted effector proteins and uses thereof
NZ749459A (en) TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
HK1226745A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
US12053510B2 (en) Treatment of neuronal ceroid lipofuscinosis